ArticleIranian journal of public health2015
The Economic Burden of Breast Cancer in Iran.
Article in Iranian journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Economic burden of five common cancers in Iran: a systematic review of cost-of-illness with a focus on healthcare resource utilization.BMC health services research · 2025Pooled it
- Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system.Cancer metastasis reviews · 2025Review
- Article
- The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study.Journal of health, population, and nutrition · 2025Article
- A Scoping Review of 20 Years Breast Cancer Screening Programs in Iran.Iranian journal of public health · 2025Review
- Pattern of burden cancer breast and relationshipin to human development index in Iran 2009 to 2019: an observational study based on the Global Burden of Diseases.BMC women's health · 2024Observational
- Evaluating the Impact of a Clinical Breast Examination Screening Program within the IraPEN Project.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Financial cost of end-of-life cancer care in palliative care units (PCUs) and non-PCUs in Iran: insights from low- and middle-income countries.Palliative care and social practice · 2024Article
- Clinical Breast Cancer Registry of IR. Iran (CBCR-IR): Study Protocol and First Results.Archives of Iranian medicine · 2023Article
- Economic burden of breast cancer: a case of Southern Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- Subjective valuation of Iranian women for screening for gene-related diseases: a case of breast cancer.BMC public health · 2023Article
- Economic burden of breast cancer in northern Serbia.Frontiers in public health · 2023Article
- The health literacy level and its related factors in Iranian women with breast cancer undergoing chemotherapy.Frontiers in public health · 2023Article
- A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022Review
- Cost-Benefit Analysis of Human Papillomavirus Vaccine in Iran.Journal of prevention (2022) · 2022Article
- The Economic Burden of Acute Myeloid Leukemia in Iran.Iranian journal of public health · 2022Article
- Estimating the Cancer Treatment Cost for 5 Common Types of Cancer with Separating Out-of-Pocket and Governmental Costs in Afghanistan, 2020.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China.Gland surgery · 2022Article
- Knowledge, Practice, Preferences and Willingness-to-Pay for Mammographic Screening Tests among Iranian Women: A Contingent Valuation Method.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study.Iranian journal of public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough breast cancer imposes a considerable economic burden on high-income countries, there is limited knowledge about its economic burden in low- and middle-income countries (LMCs), including Iran. In this study, we estimated the economic burden of breast cancer in Iran in 2010.
methodsWe used the prevalence-based approach and estimated the direct and indirect costs of all breast cancer cases in 2010. We used several data sources, including national cancer registry reports, hospital records, occupational data, and interviews with experts.
resultThe economic burden of breast cancer was US$947,374,468. Most of the cost (77%) pertained to the productivity lost due to breast cancer deaths and the direct medical cost accounted for 18.56% of the estimated total cost. Out of the US$175,860,607 as the direct medical cost, the chemotherapy cost constituted the main part ($76,755,740), of which prescriptions of trastuzumab accounted for 41% ($31,529,280).
conclusionThe economic burden of breast cancer in Iran is substantial and is expected to increase significantly due to the increasing incidence rate. Strategies for the prevention and early detection of breast cancer should be prioritized in the national cancer control program.
Indexed as
Identifiers
26587497PMC4645780W2121314053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.